The m6A-regulation and single cell effect pattern in sunitinib resistance on clear cell renal cell carcinoma: Identification and validation of targets

被引:0
|
作者
Deng, Yanxi [1 ]
Wang, Fang [1 ]
Wu, Xinhui [2 ]
Du, Kangming [3 ]
Yang, Qing [3 ]
Xia, Ting [2 ,4 ]
机构
[1] Hosp Chengdu Univ Tradit Chinese Med, Clin Lab, Chengdu, Sichuan, Peoples R China
[2] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, Dept Cardiothorac Surg, Chengdu, Sichuan, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
关键词
epigenetic; sunitinib; ccRCC; MX2; biological; CANCER; IFITM1; PROMOTES;
D O I
10.3389/fphar.2023.1131610
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Sunitinib is the main target drug for clear cell renal cell carcinoma. However, the effect of sunitinib is often limited by acquired drug resistance.Methods: The open-accessed data used in this study were obtained from different online public databases, which were analyzed using the R software. The RNA level of specific genes was detected using quantitative Real-Time PCR. Sunitinib-resistant cell lines were constructed based on protocol get from the previous study. Colony formation and Cell Counting Kit-8 assays were applied to detect cell proliferation ability.Results: In this study, through publicly available data and high-quality analysis, we deeply explored the potential biological mechanisms that affect the resistance of sunitinib. Detailed, data from GSE64052, GSE76068 and The Cancer Genome Atlas were extracted. We identified the IFITM1, IL6, MX2, PCOLCE2, RSAD2 and SLC2A3 were associated with sunitinib resistance. Single-cell analysis, prognosis analysis and m6A regulatory network were conducted to investigate their role. Moreover, the MX2 was selected for further analysis, including its biological role and effect on the ccRCC microenvironment. Interestingly, we noticed that MX2 might be an immune-related gene that could affect the response rate of immunotherapy. Then, in vitro experiments validated the overexpression of MX2 in sunitinib-resistance cells. Colony formation assay indicated that the knockdown of MX2 could remarkably inhibit the proliferation ability of 786-O-Res and Caki-1-Res when exposed to sunitinib.Conclusion: In summary, through publicly available data and high-quality analysis, we deeply explored the potential biological mechanisms that affect the resistance of sunitinib. MX2 was selected for further analysis, including its biological role and effect on the ccRCC microenvironment. Finally, in vitro experiments were used to validate its role in ccRCC.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] IDENTIFICATION OF MICRORNA REGULATING SUNITINIB RESISTANCE IN RENAL CELL CARCINOMA CELLS
    Yamaguchi, Noriya
    Yumioka, Tetsuya
    Onuma, Kunishige
    Iwamoto, Hideto
    Masago, Toshihiko
    Morizane, Shuichi
    Honda, Masashi
    Osaki, Mitsuhiko
    Okada, Futoshi
    Takenaka, Atsushi
    JOURNAL OF UROLOGY, 2017, 197 (04): : E797 - E798
  • [32] Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells
    Yamaguchi, Noriya
    Osaki, Mitsuhiko
    Onuma, Kunishige
    Yumioka, Tetsuya
    Iwamoto, Hideto
    Sejima, Takehiro
    Kugoh, Hiroyuki
    Takenaka, Atsushi
    Okada, Futoshi
    ANTICANCER RESEARCH, 2017, 37 (06) : 2985 - 2992
  • [33] Posttranslational Modifications Pattern in Clear Cell Renal Cell Carcinoma
    Ene, Corina Daniela
    Penescu, Mircea Nicolae
    Georgescu, Simona Roxana
    Tampa, Mircea
    Nicolae, Ilinca
    METABOLITES, 2021, 11 (01) : 1 - 21
  • [34] Vascular Pattern and Density in Clear Cell vs Clear Cell Papillary Renal Cell Carcinoma
    Canete-Portillo, S.
    Pena, M. Rodriguez
    Wang, D.
    Netto, G. J.
    Magi-Galluzzi, C.
    Sanchez, D. F.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S78 - S78
  • [35] Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications
    Adelaiye, Remi
    Ciamporcero, Eric
    Miles, Kiersten Marie
    Sotomayor, Paula
    Bard, Jonathan
    Tsompana, Maria
    Conroy, Dylan
    Shen, Li
    Ramakrishnan, Swathi
    Ku, Sheng-Yu
    Orillion, Ashley
    Prey, Joshua
    Fetterly, Gerald
    Buck, Michael
    Chintala, Sreenivasulu
    Bjarnason, Georg A.
    Pili, Roberto
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (02) : 513 - 522
  • [36] PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma
    Aimudula, Ainiwaer
    Nasier, Huerxidan
    Yang, Ying
    Zhang, Ruili
    Lu, Pengfei
    Hao, Jie
    Bao, Yongxing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (05): : 2389 - 2400
  • [37] RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma
    Song, Zhengshuai
    Cao, Qi
    Ruan, Hailong
    Yang, Hongmei
    Wang, Keshan
    Bao, Lin
    Cheng, Gong
    Xu, Tianbo
    Xiao, Haibing
    Wang, Cheng
    Liu, Di
    Chen, Ke
    Zhang, Xiaoping
    EXPERIMENTAL CELL RESEARCH, 2018, 372 (02) : 118 - 128
  • [38] Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma
    Peng, Qiang
    Wang, Lu
    Zhao, Danfeng
    Lv, Yulin
    Wang, Hongzhi
    Chen, Guang
    Wang, Jiaqi
    Xu, Wanhai
    JOURNAL OF CANCER, 2019, 10 (05): : 1237 - 1251
  • [39] Risk signature identification and NPRL2 affects sunitinib sensitivity in clear cell renal cell carcinoma
    Du, Xiaoyi
    Zhao, Zhipeng
    Zhao, Xin
    Wang, Hexi
    Jiang, Li
    Tang, Wei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2023, 663 : 122 - 131
  • [40] Targeting epigenetic regulation in clear cell renal cell carcinoma
    Apostoli, Anthony J.
    Lobo, Nazleen
    Prinos, Panagiotis
    Barsyte-Lovejoy, Delia
    Smith, Cheryl Arrow
    Ailles, Laurie
    CANCER RESEARCH, 2016, 76